U.K. Court Invalidates Merck Fosamax Patents

Law360, New York (November 6, 2003, 12:00 AM EST) -- The English Court of Appeal upheld the English Patents Court's ruling invalidating two Merck patents related to its Fosamax osteoporosis drug, Israeli generics drugmaker Teva Pharmaceutical Industries said Thursday.

One of the patents relates to pharmaceuticals containing the active ingredient of Merck's Fosamax and the second patent relates to its once-weekly administration, according to Teva.

Alendronate Sodium Tablets are the generic equivalent of Merck's Fosamax Tablets. The product is indicated for the treatment and prevention of osteoporosis and the treatment of Paget's disease.

Annual branded sales...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.